Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented new preclinical data from its immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The data, featured in one oral and two poster sessions, highlighted the potential of TNX-1700 and TNX-4700 as cancer immunotherapies. The findings suggest TNX-1700 may reduce inflammation and tumor progression in gastric cancer models, while TNX-4700 demonstrated promising in vitro activity targeting BTLA, a checkpoint receptor, indicating its potential as a monotherapy or in combination with other checkpoint inhibitors.
TNX-1700, a modified bacterial enzyme, showed favorable pharmacokinetics and anti-tumor activity in preclinical models. The compound is designed to degrade extracellular matrix components that contribute to tumor growth and immune suppression. The data presented at AACR support its further development for gastric cancer, a disease with high unmet need. TNX-4700, a monoclonal antibody targeting BTLA, enhances T-cell activation and anti-tumor immunity. The in vitro results suggest it could be effective alone or alongside PD-1/PD-L1 inhibitors, expanding the therapeutic options for patients who do not respond to existing immunotherapies.
Tonix Pharmaceuticals, a fully-integrated commercial-stage biotechnology company, focuses on central nervous system (CNS) and immunology treatments. Its flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in over 15 years. The company's CNS commercial infrastructure supports marketed products like Zembrace SymTouch and Tosymra for acute migraine. Tonix is also advancing TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder. Additionally, the pipeline includes TNX-2900 for Prader-Willi syndrome, TNX-4800 for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection.
The AACR data underscore Tonix's commitment to expanding its immuno-oncology pipeline. The company's product development candidates are investigational and have not been approved for any indication. More information on Tonix and its programs can be found at the company's newsroom here. The full press release is available here.
